Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 355

Sort by

Sort Order Select

Journal Articles

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Blood (2025) 146 (25): 3050–3058.

https://doi.org/10.1182/blood.2025030084

Published: 2025

Includes: Supplemental data

Journal Articles

The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma

Liliana Lucca, Ossama Kohil, Marine Cuisinier, Marie-véronique Joubert, Nadège Carrié, Anaïs Schavgoulidze, Laure Vincent, Xavier Leleu, Benjamin Hebraud, Jill Corre, Aurore Perrot, Herve Avet-Loiseau, Ludovic Martinet

Blood (2025) 146 (Supplement 1): 918.

https://doi.org/10.1182/blood-2025-918

Published: 2025

Journal Articles

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Blood (2025) 146 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2025-4076

Published: 2025

Journal Articles

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2025-2215

Published: 2025

Journal Articles

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Blood (2025) 146 (Supplement 1): 697.

https://doi.org/10.1182/blood-2025-697

Published: 2025

Journal Articles

Shifting first-line paradigms: Real-world treatment outcomes and healthcare burden in non-transplant newly diagnosed multiple myeloma in France (2015-2022)

Feng Lin, Peggy Lin, Giancarlo Pesce, Raissa Kapnang, Nadia Quignot, Lea Antoniali, Tilia Soubbotine, Xavier Leleu

Blood (2025) 146 (Supplement 1): 6353.

https://doi.org/10.1182/blood-2025-6353

Published: 2025

Journal Articles

The burden of myeloma treatment routes and locations on patients and families: Insights from a Pan-European survey

Eilidh Duncan, Silene ten Seldam, Diane Loening-Martens, Xavier Leleu, Charlotte Pawlyn, Séverine Wollenschneider, Katie Joyner, Kate Morgan

Blood (2025) 146 (Supplement 1): 6342.

https://doi.org/10.1182/blood-2025-6342

Published: 2025

Journal Articles

A comparison between subcutaneous isa-vrd from the isasocut study and intravenous isa-vrd from the imroz study in patients with transplant- ineligible newly diagnosed multiple myeloma

Arthur Bobin, Mohamad Mohty, Philippe Moreau, Hartmut Goldschmidt, Meletios Dimopoulos, Robert Orlowski, Cyrille Touzeau, Aurore Perrot, Thomas Chalopin, Mamoun Dib, Lydia Montes, Umer Khan, Mony Morisse, Rick Zhang, Corina Oprea, Florence Suzan Teisserenc, Thierry Facon, Xavier Leleu

Blood (2025) 146 (Supplement 1): 7566.

https://doi.org/10.1182/blood-2025-7566

Published: 2025

Journal Articles

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Blood (2025) 146 (Supplement 1): 5812.

https://doi.org/10.1182/blood-2025-5812

Published: 2025

Journal Articles

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Blood (2025) 146 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2025-2275

Published: 2025

Journal Articles

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Sara Bringhen, Paula Rodriguez-Otero, Mohamad Mohty, Robert Orlowski, Meletios Dimopoulos, Xavier Leleu, María-Victoria Mateos, Philippe Moreau, Sandrine Macé, Ecrem Kodas, Christine Tekle, Umer Khan, Corina Oprea, Thierry Facon

Blood (2025) 146 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2025-2267

Published: 2025

Journal Articles

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

Blood (2025) 146 (Supplement 1): 368.

https://doi.org/10.1182/blood-2025-368

Published: 2025

Journal Articles

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Blood (2025) 146 (Supplement 1): 367.

https://doi.org/10.1182/blood-2025-367

Published: 2025

Journal Articles

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2025) 146 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2025-2288

Published: 2025

Journal Articles

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Julie Castiaux, Noemie Bigot, Cyrille Hulin, Magaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Aurore Perrot, Jean-Yves Mary, Jill Corre, Herve Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon, Jerome Lambert, Salomon Manier

Blood (2025) 146 (Supplement 1): 498.

https://doi.org/10.1182/blood-2025-498

Published: 2025

Journal Articles

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

Blood (2025) 146 (Supplement 1): 497.

https://doi.org/10.1182/blood-2025-497

Published: 2025

Journal Articles

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Blood (2025) 146 (Supplement 1): 744.

https://doi.org/10.1182/blood-2025-744

Published: 2025

Journal Articles

Next-generation sequencing-based mutation profile in secondary compared to de novo acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 6069.

https://doi.org/10.1182/blood-2025-6069

Published: 2025

Journal Articles

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Blood blood.2025029999.

https://doi.org/10.1182/blood.2025029999

Published: 2025

Includes: Supplemental data

Journal Articles

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Blood (2025) 146 (6): 679–692.

https://doi.org/10.1182/blood.2024027620

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Shifting first-line paradigms: Real-world treatment outcomes and healthcare burden in non-transplant newly diagnosed multiple myeloma in France (2015-2022)

The burden of myeloma treatment routes and locations on patients and families: Insights from a Pan-European survey

A comparison between subcutaneous isa-vrd from the isasocut study and intravenous isa-vrd from the imroz study in patients with transplant- ineligible newly diagnosed multiple myeloma

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Next-generation sequencing-based mutation profile in secondary compared to de novo acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: A study from the ALWP/EBMT

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only